Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuichi Imai

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Oncoimmunology|September 19, 2017
The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinomaHirokazu Matsushita, Kosei Hasegawa, Katsutoshi Oda, et al.
British Journal of Cancer|February 1, 2020
A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancerKosei Hasegawa, Muneaki Shimada, Satoshi Takeuchi, et al.
Scientific Reports|May 24, 2023
Comprehensive hemocompatibility analysis on the application of diamond-like carbon to ePTFE artificial vascular prosthesisTakashi Goyama, Yasuhiro Fujii, Genya Muraoka, et al.
Developmental Biology|November 13, 2008
Runx1 is involved in the fusion of the primary and the secondary palatal shelvesKesinee Charoenchaikorn, Tomomasa Yokomizo, David P Rice, et al.
International Journal of Clinical Oncology|July 13, 2024
Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup studyShoji Nagao, Shin Nishio, Kazuhiro Takehara, et al.
Cancer Science|July 1, 2017
Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumorsTadaaki Nishikawa, Koji Matsumoto, Kenji Tamura, et al.
Journal of Gynecologic Oncology|July 1, 2025
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trialShin Nishio, Tadaaki Nishikawa, Masahiko Mori, et al.
Japanese Journal of Clinical Oncology|December 4, 2025
Risk-reducing mastectomy and salpingo-oophorectomy in women with hereditary breast and ovarian cancer: a single-institute experience following coverage by Japanese national medical insuranceAkimitsu Yamada, Masanori Oshi, Takumi Isa, et al.
BMC Medical Education|February 11, 2025
Enhancing clinical reasoning skills in medical students through team-based learning: a mixed-methods studyKosuke Ishizuka, Kiyoshi Shikino, Naoko Takada, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Oncoimmunology|September 19, 2017
The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinomaHirokazu Matsushita, Kosei Hasegawa, Katsutoshi Oda, et al.
British Journal of Cancer|February 1, 2020
A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancerKosei Hasegawa, Muneaki Shimada, Satoshi Takeuchi, et al.
Scientific Reports|May 24, 2023
Comprehensive hemocompatibility analysis on the application of diamond-like carbon to ePTFE artificial vascular prosthesisTakashi Goyama, Yasuhiro Fujii, Genya Muraoka, et al.
Developmental Biology|November 13, 2008
Runx1 is involved in the fusion of the primary and the secondary palatal shelvesKesinee Charoenchaikorn, Tomomasa Yokomizo, David P Rice, et al.
International Journal of Clinical Oncology|July 13, 2024
Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup studyShoji Nagao, Shin Nishio, Kazuhiro Takehara, et al.
Cancer Science|July 1, 2017
Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumorsTadaaki Nishikawa, Koji Matsumoto, Kenji Tamura, et al.
Journal of Gynecologic Oncology|July 1, 2025
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trialShin Nishio, Tadaaki Nishikawa, Masahiko Mori, et al.
Japanese Journal of Clinical Oncology|December 4, 2025
Risk-reducing mastectomy and salpingo-oophorectomy in women with hereditary breast and ovarian cancer: a single-institute experience following coverage by Japanese national medical insuranceAkimitsu Yamada, Masanori Oshi, Takumi Isa, et al.
BMC Medical Education|February 11, 2025
Enhancing clinical reasoning skills in medical students through team-based learning: a mixed-methods studyKosuke Ishizuka, Kiyoshi Shikino, Naoko Takada, et al.
Pageof 4